Prot#CB8025-21629: An 8-week, Dose Ranging, Open Label, Randomized, Phase 2 Study with a 44-Week Extension, to Evaluate the Safety and Efficacy of MBX-8025 in Subjects with Primary Biliary Cholangitis (PBC) and an Inadequate Response to or Intole

  • Flamm, Steven L (PD/PI)

Project: Research project

Project Details

Effective start/end date1/3/181/3/21


  • PRA Health Sciences (CB8025-21629 // CB8025-21629)
  • CymaBay Therapeutics, Inc. (CB8025-21629 // CB8025-21629)